Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GemPharmatech CoSHSE:688046 +2.58%77 EV-to-EBIT is 65.91 as of Sep. 22, 2026, which is 68% above its 10-year median of 39.33. GuruFocus rates SHSE:688046 with a GF Score™ of 77/100 and a GF Value™ of ¥19.74 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 381 Biotechnology companies, GemPharmatech Co ranks worse than 85.83% on this metric.
GemPharmatech Co (SHSE:688046) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
GemPharmatech Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥8,979.1 Mil.
GemPharmatech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥222.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GemPharmatech Co EV-to-EBIT Related Terms
GemPharmatech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for GemPharmatech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688046 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, GemPharmatech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GemPharmatech Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GemPharmatech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where GemPharmatech Co's EV-to-EBIT falls into.
GemPharmatech Co's current Enterprise Value is ¥14,672.0 Mil.
GemPharmatech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥222.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GemPharmatech Co (SHSE:688046) has a EV-to-EBIT of 65.91 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GemPharmatech Co and its competitors. This is 68% above median its historical median of 39.33. Over the past decade, GemPharmatech Co's EV-to-EBIT has ranged from 16.28 to 75.87. According to the industry distribution chart, GemPharmatech Co ranks #327 out of 381 companies in the Biotechnology industry, placing it in the top 85.8%.
Is GemPharmatech Co's EV-to-EBIT too high?
GemPharmatech Co's current EV-to-EBIT of 65.91 is 68% above median its 10-year median of 39.33. Over the past 10 years, this metric has ranged from a low of 16.28 to a high of 75.87. The Biotechnology industry median EV-to-EBIT is 14.08. GemPharmatech Co's value of 65.91 is 368.1% above this industry median. Based on the distribution chart, GemPharmatech Co ranks #327 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GemPharmatech Co has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GemPharmatech Co ranks #327 out of 381 companies for EV-to-EBIT. This places GemPharmatech Co in the lower half of its industry. The industry median EV-to-EBIT is 14.08. GemPharmatech Co's value of 65.91 is 368.1% above this benchmark. Historically, GemPharmatech Co's own EV-to-EBIT has ranged from 16.28 to 75.87 over the past decade. While the company's 10-year median is 39.33 vs. the industry median of 14.08, GemPharmatech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.08, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GemPharmatech Co's current EV-to-EBIT of 65.91 is 368.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GemPharmatech Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GemPharmatech Co's current EV-to-EBIT is 65.91, which is 68% above median its own 10-year median of 39.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.74, compared to a current price of ¥37.73 — trading 91.1% above its estimated fair value. The current EV-to-EBIT is 65.91, which is 68% above median its 10-year median of 39.33 and 368.1% above the Biotechnology industry median of 14.08. GemPharmatech Co's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current EV-to-EBIT is 65.91 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?
Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued.
The current stock price of ¥37.73 is trading 91.1% above its estimated GF Value™ of ¥19.74.
GuruFocus considers GemPharmatech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688046:
EV-to-EBIT: 65.91 (68% above median its 10-year median of 39.33)
GF Value™: ¥19.74 vs. price of ¥37.73 (91.1% above fair value)
Industry Position: 368.1% above the Biotechnology median (#327 of 381)
No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
77GF Score
Get the complete analysis for SHSE:688046
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688046 has been successfully added to your 
